Skip to content
thestock.space

On 6 Nov 2026, Choksi Laboratories was priced at ₹199.65, or 64.2× trailing earnings, against an industry P/E of 52.8×, and the shares are 12% below their 52-week high. Its ROCE of 12% is the second-lowest among the 7 largest Diagnostics & Research peers, and sales grew 10% a year over 3 years while net profit fell 15%. Debt is 1.34× equity. It is a small-cap company with a market cap of ₹139 Cr, ranked 12th of 18 Diagnostics & Research companies by market cap; the shares rose 36% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹200.00
Day high
₹200.05
Day low
₹196.50
Prev. close
₹201.50
Volume
349

Health check

1 good · 1 fair · 4 to check
  • ReturnsAhead

    +36.4% over a year, better than 5 of 7 peers.

  • Price tagPricier

    P/E 64.2 vs industry 52.8.

  • GrowthSlow

    Sales +10.1%, profit −15.1% a year over 3 years.

  • ProfitabilityWeak

    ROCE 12.3% vs peer median 19.1%.

  • Balance sheetFair

    Debt 1.34× equity, interest covered 2.1×, Piotroski 7 of 9.

  • Red flags1 to check

    Return on equity is low at 8.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Small cap

₹139 Cr, #12 of 18 in its industry by size.

Defensive

Beta 0.29 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹47 Cr · profit ₹2 Cr
Market cap
₹139 Cr
Small cap
P/E
64.2
Industry 52.8
Price to book
5.45
Peers 11.99
Dividend yield
0.00%
ROE
8.0%
Peers 17.7%
ROCE
12.3%
Peers 19.1%
Debt to equity
1.34
Debt ₹34 Cr
EPS (TTM)
₹3.11
OPM (TTM)
26.8%
Net margin 4.6%
Sales growth
+7.3%
Latest quarter vs a year ago
Profit growth
+51.3%
Latest quarter vs a year ago
Price to sales
2.97
EV/EBITDA 13.8

Strengths and risks

Strengths

  • Quarterly profit up 51.3% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 8.0%.

Derived automatically from reported figures. Not a recommendation.

About Choksi Laboratories

Choksi Laboratories Limited provides contract testing and analytical services in India. The company offers construction material analysis; environmental management analysis, such as ambient and indoor air quality monitoring, fugitive emissions, stack emission monitoring, soil testing, waste water testing, sound level monitoring, and illumination survey; calibration services comprising electro technical, thermal, dimension, pressure, mass and volume,…

Headquarters
Indore
Employees
364
Sector
Healthcare
ISIN
INE493D01013
Website
choksilab.in

Price range

52 weeks

₹81.85₹227.90

Today

₹196.50₹200.05
Avg volume (3M)
14.2K
1-year return
plus 36.4%
From 52-week high
minus 12.4%

Peers · Diagnostics & Research

Compare with peersScreen the whole industry
Company
SAILIFESai Life Sciences1,785.10plus 11.95%37,929101.515.2218.1%15.1%28.7%21.3%226.8%0.00%plus 72.7%
LALPATHLABDr. Lal Path Labs1,970.00plus 0.16%32,94156.511.9925.7%22.6%30.2%11.1%28.3%1.02%plus 24.7%
SYNGENESyngene International417.30plus 0.77%16,77290.33.468.3%3.9%25.7%5.4%−12.0%0.30%minus 36.0%
VIJAYAVijaya Diagnostic Centre1,468.60plus 2.15%15,12674.414.2919.1%21.2%43.1%21.0%26.9%0.14%plus 40.2%
METROPOLISMetropolis Healthcare568.75minus 0.39%11,80352.87.1715.7%14.6%21.7%12.7%10.0%0.35%plus 12.5%
THYROCAREThyrocare Technologies493.10plus 0.68%7,84855.014.7533.8%26.4%32.2%16.7%36.2%1.89%plus 8.3%
VIMTALABSVimta Labs496.45minus 2.14%2,21927.94.5221.0%17.7%34.7%8.9%17.2%0.40%minus 23.3%
CHOKSILAChoksi Laboratories199.65minus 0.92%13964.25.4512.3%8.0%26.8%10.1%−15.1%0.00%plus 36.4%
Median of 7 peers–0.68%15,12656.511.9919.1%17.7%30.2%12.7%26.9%0.35%12.5%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
11.211.110.812.812.1
8.38.28.29.18.8
2.92.92.63.73.3
25.8%26.3%24.3%28.9%27.2%
000.100
0.60.70.80.70.7
1.71.71.81.92
––0.8–0
0.60.60.91.10.6
38.6%57.0%65.7%6.7%2.8%
0.40.20.310.6
0.550.350.451.470.84

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+10.1%
Profit CAGR 3Y
−15.1%
EPS CAGR 3Y
−15.1%
ROE
8.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
34.436.741.846
–+6.5%+13.9%+10.1%
2426.330.333.5
10.410.411.512.5
30.3%28.4%27.5%27.2%
0.2−000.2
3.532.72.8
5.55.76.57.1
2.1–−0.20.4
3.71.72.23.2
13.7%33.3%29.3%38.5%
3.21.11.52
–minus 65.4%+37.3%+29.0%
4.611.592.192.82

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7777
14.115.216.618.6
32.430.929.234.2
6.88.912.612.2
60.46265.371.9
44.746.147.151.5
02.7–0.4
0.30.50.80.8
0.81.10.70.4
14.511.616.718.8
60.46265.371.9

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8.311.611.87.9
−0.7−6.6−7.6−7.1
−7.6−4.6−4.2−1.2
−0.10.3−0−0.4
−4.2−7.1−7.7−8.2
4.14.54.1−0.3

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you